COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition

Bruno Guedes Baldi; Elzbieta Radzikowska; Vincent Cottin; Daniel F Dilling; Ali Ataya; Carlos Roberto Ribeiro Carvalho; Sergio Harari; Matthew Koslow; Jan C Grutters; Yoshikazu Inoue; Nishant Gupta; Simon R Johnson

doi:10.1016/j.chest.2021.12.640

COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition

Bruno Guedes Baldi, Elzbieta Radzikowska, Vincent Cottin, Daniel F Dilling, Ali Ataya, Carlos Roberto Ribeiro Carvalho, Sergio Harari, Matthew Koslow, Jan C Grutters, Yoshikazu Inoue, Nishant Gupta, Simon R Johnson

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	1589-1593
Number of pages	5
Journal	Chest
Volume	161
Issue number	6
Early online date	21 Dec 2021
DOIs	https://doi.org/10.1016/j.chest.2021.12.640
Publication status	Published - Jun 2022
Externally published	Yes

Access to Document

10.1016/j.chest.2021.12.640

Cite this

Baldi, B. G., Radzikowska, E., Cottin, V., Dilling, D. F., Ataya, A., Carvalho, C. R. R., Harari, S., Koslow, M., Grutters, J. C., Inoue, Y., Gupta, N., & Johnson, S. R. (2022). COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition. Chest, 161(6), 1589-1593. https://doi.org/10.1016/j.chest.2021.12.640

@article{aa3cba9ad4944b39bbb4ff45bca5088a,

title = "COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition",

author = "Baldi, {Bruno Guedes} and Elzbieta Radzikowska and Vincent Cottin and Dilling, {Daniel F} and Ali Ataya and Carvalho, {Carlos Roberto Ribeiro} and Sergio Harari and Matthew Koslow and Grutters, {Jan C} and Yoshikazu Inoue and Nishant Gupta and Johnson, {Simon R}",

note = "Funding Information: FUNDING/SUPPORT: D. F. D. is supported by the National Institutes of Health [Grant U01HL131755]. Y. I. is supported by the Japanese Ministry of Health Labour, and Welfare. N. G. is supported by the National Institutes of Health [Grants U01HL131755 and R34HL138235] and the LAM Foundation. S. R. J. is supported by the Medical Research Council, National Institute for Health Research, British Lung Foundation , LAM Action, and the LAM Foundation. Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: D. F. D. is a member of the board of directors of the LAM Foundation. Y. I. reports advising of and lecture fees from Boehringer Ingelheim, Taiho, Roche, Shionogi, Galapagos, and Savara. None declared (B. G. B., E. R., V. C., A. A., C. R. R. C., S. H., M. K., J. C. G., N. G., S. R. J.).FUNDING/SUPPORT: D. F. D. is supported by the National Institutes of Health [Grant U01HL131755]. Y. I. is supported by the Japanese Ministry of Health Labour, and Welfare. N. G. is supported by the National Institutes of Health [Grants U01HL131755 and R34HL138235] and the LAM Foundation. S. R. J. is supported by the Medical Research Council, National Institute for Health Research, British Lung Foundation, LAM Action, and the LAM Foundation.",

year = "2022",

month = jun,

doi = "10.1016/j.chest.2021.12.640",

language = "English",

volume = "161",

pages = "1589--1593",

journal = "Chest",

issn = "0012-3692",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - COVID-19 in Lymphangioleiomyomatosis

T2 - An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition

AU - Baldi, Bruno Guedes

AU - Radzikowska, Elzbieta

AU - Cottin, Vincent

AU - Dilling, Daniel F

AU - Ataya, Ali

AU - Carvalho, Carlos Roberto Ribeiro

AU - Harari, Sergio

AU - Koslow, Matthew

AU - Grutters, Jan C

AU - Inoue, Yoshikazu

AU - Gupta, Nishant

AU - Johnson, Simon R

N1 - Funding Information: FUNDING/SUPPORT: D. F. D. is supported by the National Institutes of Health [Grant U01HL131755]. Y. I. is supported by the Japanese Ministry of Health Labour, and Welfare. N. G. is supported by the National Institutes of Health [Grants U01HL131755 and R34HL138235] and the LAM Foundation. S. R. J. is supported by the Medical Research Council, National Institute for Health Research, British Lung Foundation , LAM Action, and the LAM Foundation. Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: D. F. D. is a member of the board of directors of the LAM Foundation. Y. I. reports advising of and lecture fees from Boehringer Ingelheim, Taiho, Roche, Shionogi, Galapagos, and Savara. None declared (B. G. B., E. R., V. C., A. A., C. R. R. C., S. H., M. K., J. C. G., N. G., S. R. J.).FUNDING/SUPPORT: D. F. D. is supported by the National Institutes of Health [Grant U01HL131755]. Y. I. is supported by the Japanese Ministry of Health Labour, and Welfare. N. G. is supported by the National Institutes of Health [Grants U01HL131755 and R34HL138235] and the LAM Foundation. S. R. J. is supported by the Medical Research Council, National Institute for Health Research, British Lung Foundation, LAM Action, and the LAM Foundation.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85127803078&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2021.12.640

DO - 10.1016/j.chest.2021.12.640

M3 - Letter

C2 - 34942174

SN - 0012-3692

VL - 161

SP - 1589

EP - 1593

JO - Chest

JF - Chest

IS - 6

ER -

COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition

Access to Document

Other files and links

Cite this